J B Chemicals & Pharamaceuticals Ltd share price today (on 1 October 2023).

We Provide Best stock tips for J B Chemicals & Pharamaceuticals Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of J B Chemicals & Pharamaceuticals Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.

Get Free Stock Tips for J B Chemicals & Pharamaceuticals Ltd

J. B. Chemicals & Pharmaceuticals Ltd. is a global pharmaceutical company manufacturing a wide range of innovative specialty medicines for domestic and international markets. A flagship company of the Unique Group, it is also known to many as Unique.Originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals in Dec.'76, J B Chemicals & Pharmaceuticals (JBC) manufactures basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity.
It has entered into an MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from Apr.'00. Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines. In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment ie Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new products Cephalosporins, Moviz and its expansion Movi 3D and a nueropsychiatry product through Zephyr for the first time. A 100% EOU manufacturing facility at Panoli for production of Gel,Ointment was commissioned during 2001-02 at a cost of Rs. 21 crores and the same was financed through internal accruals.
To manufacture 'DOKTOR MOM' lozenges the company is setting up two manufacturing units at Daman at an capital outlay of Rs. 28 crores,which is to be financed through internal accruals. The commercial production of the Doktor Mom lozenges at its 100% Export Oriented Unit, started from 1 Sep. 2003 and tablets from 1, Jan. 2004 in Daman.Doktor Mom',the company's brand,was adjudged the Most Trusted European Brand by Reader's Digest in the cold and cough segment for the fourth consecutive year in 2003-04. During 2004-05, the company received approval for its pharmaceutical manufacturing unit from TGA (Australia).During 2004-05, the company plants were approved by US-FDA,TGA-Australia,EDQM, MCC-South Africa, INVIMA(Colombia) and MHRA(UK). During 2004-05, the company is setting up a new facility conforming to international standards in Panoli (Gujarat) to manufacture contrast media products by June 2006.
During 2004-05, the company has planned to set up a wholly owned subsidiary in Moscow, Russia, called 'Unique Pharmaceuticals Laboratories' with the intial investment of $ 3 million. During 2005, the company entered into two agreements, one with Pharma-a-Care Pharmaceuticals Pte. Ltd in Australia to develop its niche products in Australian market and another with Ranbaxy Laboratories to enter in the Romanian market. The company has subdivided the value of the share from Rs. 10/- per share to Rs.2/- per share with effective from 05, April 2005. During 2005-2006, the company has proposed to amalgamate its wholly owned subsidiary viz. lekar healthcare ltd with itself. The company has fixed April 1, 2006 as the appointed date.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues decreased with -7.37%, from INR 896.95 tens of millions to INR 830.85 tens of millions. Operating result decreased from INR 159.45 tens of millions to INR 99.7 tens of millions which means -37.47% change. The results of the period reached INR -83.78 tens of millions at the end of the period against INR 138.35 tens of millions last year. Return on equity (Net income/Total equity) went from 20.01% to -8.64%, the Return On Asset (Net income / Total Asset) went from 15.78% to -6.99% and the Net Profit Margin (Net Income/Net Sales) went from 15.42% to -10.08% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 123.49% compared to 126.80% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 5.25 to 4.11 when compared to the previous year.